ProBio Establishes Cell and Gene Therapy CDMO Center of Excellence in Hopewell, New Jersey, Specializing in Plasmid DNA and Viral Vector Manufacturing

September 6, 2026

ProBio USA

Overview

ProBio has opened a Cell and Gene Therapy Center of Excellence in Hopewell, New Jersey, focusing on the development and GMP manufacturing of plasmid DNA and viral vectors. This new facility is designed to meet stringent FDA regulatory requirements and aims to support the rapid development and commercialization of advanced therapies through close client collaboration. This expansion reinforces ProBio’s position as a global CDMO in the cell and gene therapy sector.

In Depth

Key Findings

ProBio has established a new strategic stronghold in the contract development and manufacturing organization (CDMO) market for cell and gene therapies. The company officially inaugurated a Center of Excellence in Hopewell, New Jersey, USA, dedicated to the development and GMP (Good Manufacturing Practice) manufacturing of plasmid DNA and viral vectors.

Technical / Clinical Details

This state-of-the-art facility will primarily focus on the production of plasmid DNA, a crucial component of gene therapies, and viral vectors (such as AAV, lentivirus, and adenovirus), which are essential tools for gene delivery. Designed to be fully compliant with the stringent regulatory requirements of the FDA (U.S. Food and Drug Administration), the facility guarantees the quality and safety of all manufactured materials. It offers end-to-end services, ranging from early-stage research and development to the production of materials for pre-clinical and clinical trials, and ultimately, commercial-scale manufacturing. Advanced bioprocess technologies and robust quality control systems are implemented to provide customized solutions tailored to the specific needs of each project, thereby supporting the efficient progression of client pipelines.

Background & Context

While the cell and gene therapy sector holds immense potential to revolutionize disease treatment, its complex manufacturing processes and rigorous regulatory demands present significant barriers to commercialization. The production of plasmid DNA and viral vectors, in particular, requires highly specialized expertise and substantial capital investment in equipment. In this context, specialized CDMOs like ProBio play a vital role in accelerating industry innovation by enabling biotechnology companies and pharmaceutical firms to reduce the burden and cost of building their own large-scale manufacturing facilities, allowing them to concentrate on R&D. Securing a strategic location in the U.S. market is essential for enhancing access to clients in one of the world’s largest pharmaceutical markets.

Strategic Significance & Outlook

The establishment of this new center in Hopewell, New Jersey, marks a critical step for ProBio in solidifying its position as a leading global CDMO in the cell and gene therapy sector. This facility is poised to accelerate the market entry of innovative gene and cell therapies, ultimately contributing to delivering life-saving treatments to more patients. ProBio’s adherence to FDA regulations and its client-centric approach lay a strong foundation for sustained growth in this rapidly evolving field. The company’s specialized expertise and expanded capabilities are expected to meet the diverse needs in the development of advanced therapeutic products.

Source: https://www.probiocdmo.com/company-introduction

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.